Researchers at the Hebrew University of Jerusalem, led by Dr. Raphael Mechoulam, who is known for discovering cannabidol (CBD), observedCBDreceptors in other bodily tissues.
The findings suggest that the therapeutic effects of CBD, a non-psychoactive compound, could be modified to fit different receptors. Different illness such as diabetes, atherosclerosis andcardiovascular diseasecould therefore be treated.
A study was conducted on rats with infarcts (areas of dead tissue) due to a failure of blood supply. When pretreated with CBD, these infarcts were 30 per cent smaller.
Chronic inflammation has long been known to play a key role in the development ofinsulin resistanceand thereforetype 2 diabetes. The researchers believe that the anti-inflammatory properties of CBD could treat this inflammation and therefore improve the body's metabolism.
In addition, theimmune system, cell growth,sugarmetabolism and heart function all also appear to prospectively benefit from CBD�s anti-inflammatory properties.
ISA Scientific, an Israeli company, recently signed a worldwide collaboration and licensing deal to establish therapies containing CBD.
In a statement, ISA Scientific Chief Executive Officer Mark J. Rosenfeld said: "The licensing agreement is very well timed because our Phase 1 clinical trials on dosing and safety are now underway in Israel, and arrangements for Phase 2 trials ontreating diabetesandchronic painare in process."